NEW YORK and DUBLIN and TORONTO, May 29, 2026 (GLOBE NEWSWIRE) — The Company announces that the following resolutions were put forward at its Annual General Meeting (“AGM”) held on May 29, 2026. All resolutions with the exception of 3(c), as set out in the Notice of Meeting, were duly passed on a poll. The number of votes for and against each of the resolutions put before the meeting and the number of votes withheld were as follows:Resolutions Votes For1 Votes Against1 Total votes2 Votes Withheld3No. of shares % No. of shares % No. of shares No. of shares1. By separate resolutions, to Elect /Re-elect:            1(a) John Bryant 126,067,313 92.42% 10,333,778 7.58% 136,401,091 1,037,6031(b) Peter Jackson 124,714,415 91.43% 11,688,566 8.57% 136,402,981 1,035,7131(c) Robert (Dob) Bennett 130,601,155 95.75% 5,799,617 4.25% 136,400,772 1,037,9221(d)...

The primary endpoint of mean change in best corrected visual acuity (BCVA) from baseline to week 52 in both Phase 3 trials was not met The secondary endpoint of retinal thickness showed a substantial and persistent reduction with OCS-01 vs vehicle in both trialsOculis will focus its developmental efforts and financial resources on the ongoing Privosegtor PIONEER registrational program in optic neuropathies and the Licaminlimab PREDICT-1 registrational trial in dry eye diseaseFinancial position remains strong with $278 million in cash, cash equivalents, and short-term investments as of March 31, 2026, providing cash runway into 2H 2029 Conference call today at 4:30 pm ETZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough...

According to preliminary unaudited data, the sales revenue of AB Pieno žvaigždės in the first three months of 2026 was EUR 52.1 million, or 0.5% less than a year ago (sales revenue for the first three months of 2025 was EUR 52.3 million). EBITDA in the first three months of 2026 was EUR 4.7 million, compared to EBITDA of EUR 2.0 million a year ago. In the first three months of 2026, the company generated a profit before tax of EUR 3.1 million. In the first three months of 2025, the company generated a profit before tax of EUR 0.2 million.Laimonas Vaškevičius CFO +370 52461419Attachment2026_q1_en_eur_solo_ias

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD) announced today that management will host a conference call to discuss the recent FDA approval of Afrezza® for use in children and adolescents aged 6 and older living with diabetes at 4:30 p.m. Eastern on Friday, May 29, 2026. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD and Kevin Kaiserman, MD, Senior Vice President, Therapeutic Area Head-Diabetes. Links to the live audio webcast of the presentation will be available on MannKind Corporation’s website at: https://investors.mannkindcorp.com/events-and-presentations. Recorded versions will also be available on the website for approximately 90 days following the conference. About MannKindMannKind Corporation (Nasdaq: MNKD) is...

SINGAPORE, May 29, 2026 (GLOBE NEWSWIRE) — Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced that it completed a reverse stock split on May 27, 2026, and requested  a hearing before the Nasdaq Hearings Panel (the “Panel”), in response to a staff determination letter (the “Letter”) received on May 27, 2026, from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”). The Letter notified the Company that, due to the Company’s failure to regain compliance with a minimum bid price of $1.00 per share requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2)...

BEIJING, CHINA, May 29, 2026 (GLOBE NEWSWIRE) — Kun Peng International Ltd. (OTCQB: KPEA) (the “Company”) announced today that a 1-for-ten (1:10) reverse split of its $0.0001 par value common stock (the “Reverse Stock Split”), which was approved by its Board of Directors and its shareholders on January 20, 2026, will be effective in the marketplace as of June 2, 2026. The Reverse Stock Split will decrease the Company’s issued and outstanding shares of common stock from 400,000,000 shares to approximately 40,000,000 shares. The Board of Directors and shareholders also approved an amendment to the Company’s Articles of Incorporation to decrease the total authorized shares of the Company’s common stock from 1,000,000,000 to 100,000,000 shares and to increase the par value of the common stock from $0.0001 to $0.001. The Reverse Stock...